cellectis 代理

详细介绍

产品咨询

世界*实验材料供应商 Cellectis正式上海金畔为其中国代理， Cellectis在一直是行业的*,一直为广大科研客户提供zui为优质的产品和服务,上海金畔一直秉承为中国科研客户带来的产品，的服务， Cellectis就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获

 Cellectis中国代理, Cellectis上海代理， Cellectis北京代理，Cellectis广东代理， Cellectis江苏代理Cellectis湖北代理,Cellectis天津,Cellectis黑龙江代理,Cellectis内蒙古代理,Cellectis吉林代理,Cellectis福建代理, Cellectis江苏代理, Cellectis浙江代理, Cellectis四川代理,

Cellectis BioResearch公司成立于2008年6月，目前约有10名员工。公司正在开发用于制备稳定细胞克隆的先进产品，由于采用了巨核酸酶1技术，能够在预先确定的基因组位点上整合兴趣基因的单一副本：部分试剂盒包含了改良的细胞，而另一些仅包含一种定点于兴趣基因组上某一位点的巨核酸酶，例如人类基因组。
 

公司：http://www.cellectis.com/

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering – based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology – to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

上海金畔生物科技有限公司